Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHYSIOLYTE IN PLASTIC CONTAINER vs PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Physiolyte is an isotonic crystalloid solution that provides electrolytes and water to maintain or restore intravascular volume and correct fluid and electrolyte imbalances. The mechanism involves distribution of fluids between intravascular and interstitial spaces, with electrolytes contributing to osmotic balance and physiological functions.
The drug is a bicarbonate-based peritoneal dialysis solution that buffers metabolic acidosis, removes uremic toxins, and corrects electrolyte imbalances via diffusion and ultrafiltration across the peritoneal membrane. It does not have a traditional receptor-mediated mechanism.
Maintenance of fluid and electrolyte balance,Replacement of fluid and electrolyte losses in patients with dehydration or hypovolemia,Correction of mild metabolic acidosis (due to lactate or acetate buffer)
FDA-approved for continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD) in patients with end-stage renal disease (ESRD),Off-label uses include acute kidney injury (AKI) requiring dialysis in select settings
Intravenous infusion; dose determined by clinical condition (e.g., dehydration, electrolyte replacement). Typical adult: 500–1000 m L as a single infusion; rate based on clinical status.
Intravenous infusion only. Each 1000 m L bag contains 4 g of amino acids and 2.5 g of lipids. Typical adult dose: 1.5-2.0 g/kg/day of amino acids (equivalent to 37.5-50 m L/kg/day) and 1.0-1.5 g/kg/day of lipids. Administer at a rate not to exceed 0.11 g/kg/hour of amino acids and 0.15 g/kg/hour of lipids. For a 70 kg patient, this equals approximately 2.6-3.5 L/day.
The terminal elimination half-life of the infused crystalloid components is not applicable as a single value; the half-life of water is approximately 30–60 minutes in healthy individuals, but varies with renal function. Electrolytes have longer half-lives (e.g., Na+ ~12–24 hours). Clinical context: In renal impairment, half-life is prolonged.
Calcium: terminal half-life 4-6 hours in patients with normal renal function; magnesium: terminal half-life 3-5 hours. Prolonged in renal impairment.
The components of Physiolyte (sodium, chloride, potassium, calcium, magnesium, and acetate) are not metabolized; they are excreted primarily by the kidneys. Acetate is rapidly metabolized in the liver to bicarbonate.
The solution components (bicarbonate, lactate, dextrose, electrolytes) are not metabolized by the liver; bicarbonate and lactate are buffer precursors converted via endogenous pathways; dextrose is absorbed and metabolized systemically; electrolytes are regulated by renal and non-renal mechanisms.
Physiolyte is a balanced crystalloid solution; its components (electrolytes and water) are excreted primarily via renal elimination. Water is eliminated by kidneys (urine), lungs (insensible loss), and skin (sweat). Electrolytes (Na+, K+, Ca2+, Mg2+, Cl-, acetate, gluconate) are predominantly excreted renally with minimal biliary or fecal elimination (<5%).
Primarily renal excretion; ~70% of calcium dose and ~60% of magnesium dose excreted unchanged in urine. Fecal elimination accounts for ~20% and ~30%, respectively. Biliary excretion is minimal.
The components of Physiolyte (electrolytes) do not significantly bind to plasma proteins; protein binding is negligible (<5%).
Calcium: ~40-50% bound to albumin; magnesium: ~25-30% bound to albumin. Binding decreases in hypoalbuminemia.
Volume of distribution for crystalloid solutions is approximately 0.2–0.25 L/kg for water and electrolytes, corresponding to the extracellular fluid volume. Clinical meaning: Rapid redistribution from intravascular to interstitial space (about 75% leaves vasculature within 1 hour).
Calcium: 0.25-0.4 L/kg; magnesium: 0.5-0.7 L/kg. Indicates distribution into extracellular fluid and bone (calcium) or intracellular and bone (magnesium).
Intravenous: 100% bioavailability. Not administered orally.
Intravenous: 100%. Intraperitoneal: ~70-80% (dependent on dwell time and concentration). Oral: ~30-40% for calcium and ~40-60% for magnesium (varies with formulation and GI factors).
No specific dose adjustment; use with caution in renal impairment due to risk of fluid/electrolyte overload. Monitor serum electrolytes and renal function.
For GFR 30-60 m L/min: reduce amino acid dose to 0.8 g/kg/day. For GFR <30 m L/min: reduce to 0.6 g/kg/day. Lipids may require adjustment based on triglyceride levels. Avoid in severe renal failure unless on dialysis.
No specific dose adjustment; use with caution in hepatic impairment due to potential fluid/electrolyte imbalances.
Child-Pugh A: no adjustment. Child-Pugh B: reduce amino acids to 1.0 g/kg/day. Child-Pugh C: avoid use or reduce to 0.5 g/kg/day with close monitoring for encephalopathy. Lipids may be given at standard doses but monitor triglycerides.
Intravenous infusion; dose determined by weight and clinical condition. Typical: 20–30 m L/kg as a single infusion; adjust based on ongoing losses and maintenance requirements.
Neonates and infants: amino acids 2.0-3.0 g/kg/day, lipids 1.0-3.0 g/kg/day. Children 1-10 years: amino acids 1.5-2.5 g/kg/day, lipids 1.0-2.0 g/kg/day. Administer via continuous infusion over 24 hours. Monitor serum triglycerides, bilirubin, and liver function.
Use with caution due to increased risk of fluid overload and electrolyte disturbances; monitor renal function and fluid status; adjust rate and volume as needed.
Use caution; start at low end of adult dosing (amino acids 1.2 g/kg/day, lipids 1.0 g/kg/day). Monitor renal function (creatinine clearance) and fluid status due to increased risk of fluid overload. No specific dose adjustments except based on renal function.
None.
Not for intravenous use. Peritoneal dialysis should be performed under strict aseptic technique to prevent peritonitis. Use only in patients with intact peritoneal membrane and no contraindications to peritoneal dialysis.
Use with caution in patients with congestive heart failure, renal impairment, or conditions that may cause fluid overload,Monitor serum electrolytes, fluid balance, and renal function during therapy,Not recommended for use in neonates or infants without careful monitoring due to risk of hypernatremia,Avoid rapid or large-volume infusions in patients with compromised cardiovascular or renal function
Monitor serum electrolytes, glucose, and acid-base status frequently. Risk of hyperglycemia, hypernatremia, hypokalemia, hypocalcemia, and metabolic alkalosis. Peritonitis and catheter-related infections are major complications. Avoid in patients with severe lactic acidosis or hypokalemia. Use caution in patients with glucose intolerance or liver disease.
Hypersensitivity to any component,Severe renal impairment (anuria or oliguria),Hyperkalemia (for solutions containing potassium),Hypermagnesemia (for solutions containing magnesium),Hypercalcemia (for solutions containing calcium),Severe metabolic alkalosis,Concurrent administration with certain drugs that may cause adverse interactions (e.g., potassium-sparing diuretics, ACE inhibitors)
Absolute: Hypersensitivity to any component, pre-existing severe metabolic alkalosis, documented non-functioning peritoneal membrane, or conditions compromising peritoneal integrity (e.g., extensive adhesions, diaphragmatic defects). Relative: Uncontrolled hyperglycemia, severe hypokalemia, or recent abdominal surgery.
No specific food interactions. However, consider the patient's overall fluid and electrolyte status; avoid excessive intake of sodium or potassium-rich foods if electrolyte imbalances are present.
No specific food interactions. However, patients should maintain a diet appropriate for chronic kidney disease on peritoneal dialysis, including controlled intake of potassium, phosphorus, and fluids as directed by their healthcare provider.
Physiolyte is a balanced electrolyte solution. No teratogenic effects reported. Considered low risk in all trimesters when used as directed.
Limited data; no evidence of teratogenicity in animal studies; avoid if possible in first trimester due to theoretical risks of uremic toxin accumulation.
Physiolyte is an electrolyte solution; its components are normal constituents of breast milk. M/P ratio not applicable. Considered compatible with breastfeeding.
Excreted into breast milk in low amounts; M/P ratio not established; compatible with breastfeeding with monitoring of infant electrolytes.
No specific dose adjustments required for pregnancy. Monitor for altered fluid requirements due to physiologic changes.
Increased plasma volume in pregnancy may require dose adjustments; monitor serum potassium and calcium; hemofiltration dose may need increased frequency or volume.
Physiolyte (balanced electrolyte solution) is isotonic with plasma and contains acetate as a buffer. Do not administer with blood products due to risk of clotting. Monitor serum electrolytes, renal function, and fluid balance during infusion. Caution in patients with heart failure, renal impairment, or hyperkalemia.
PHOXILLUM BK 4/2.5 is a peritoneal dialysis solution containing 4% icodextrin and 2.5% amino acids. It is used for one exchange per day in continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD). Avoid use in patients with known hypersensitivity to icodextrin or amino acids. Monitor serum osmolality and glucose levels, as icodextrin may interfere with glucose oxidase-based glucometers, leading to falsely elevated readings. Use with caution in patients with liver disease due to potential amino acid accumulation.
This solution is used to replace fluids and electrolytes in your body.,Tell your healthcare provider if you have kidney disease, heart disease, or are on a low-salt diet.,Report any signs of fluid overload: shortness of breath, swelling, or rapid weight gain.,Do not mix this solution with other medications unless directed by your provider.,This product is sterile and for single use only; discard any unused portion.
Use only one bag per day, typically for the long dwell (overnight).,Do not use if the solution is cloudy or the bag is damaged.,Store at room temperature, away from direct sunlight.,Monitor for signs of infection like redness, swelling, or drainage at the catheter site.,Report any unusual abdominal pain or cloudy effluent immediately.,If using a glucose meter, ensure it is not affected by icodextrin; consider using a glucose dehydrogenase-based meter.,Maintain a balanced diet as amino acids may affect protein intake needs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHYSIOLYTE IN PLASTIC CONTAINER vs PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, answered by our medical review team.
PHYSIOLYTE IN PLASTIC CONTAINER is a Irrigation Solution that works by Physiolyte is an isotonic crystalloid solution that provides electrolytes and water to maintain or restore intravascular volume and correct fluid and electrolyte imbalances. The mechanism involves distribution of fluids between intravascular and interstitial spaces, with electrolytes contributing to osmotic balance and physiological functions.. PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER is a Irrigation Solution that works by The drug is a bicarbonate-based peritoneal dialysis solution that buffers metabolic acidosis, removes uremic toxins, and corrects electrolyte imbalances via diffusion and ultrafiltration across the peritoneal membrane. It does not have a traditional receptor-mediated mechanism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHYSIOLYTE IN PLASTIC CONTAINER and PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Irrigation Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHYSIOLYTE IN PLASTIC CONTAINER is: Intravenous infusion; dose determined by clinical condition (e.g., dehydration, electrolyte replacement). Typical adult: 500–1000 m L as a single infusion; rate based on clinical status.. The standard adult dose of PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER is: Intravenous infusion only. Each 1000 m L bag contains 4 g of amino acids and 2.5 g of lipids. Typical adult dose: 1.5-2.0 g/kg/day of amino acids (equivalent to 37.5-50 m L/kg/day) and 1.0-1.5 g/kg/day of lipids. Administer at a rate not to exceed 0.11 g/kg/hour of amino acids and 0.15 g/kg/hour of lipids. For a 70 kg patient, this equals approximately 2.6-3.5 L/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHYSIOLYTE IN PLASTIC CONTAINER and PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHYSIOLYTE IN PLASTIC CONTAINER is classified as Category C. Physiolyte is a balanced electrolyte solution. No teratogenic effects reported. Considered low risk in all trimesters when used as directed.. PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER is classified as Category C. Limited data; no evidence of teratogenicity in animal studies; avoid if possible in first trimester due to theoretical risks of uremic toxin accumulation.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.